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A
rationale for using mAbs in therapy is that they may act as "magic bullets"
and
damage the cells they bind to, either through complement-mediated cyto-
toxicity
or the delivery of toxins or drugs (1-3)
.
However, mAbs are not just
inert
messengers of destruction
.
They themselves behave as antigens when
injected
into a different species
.
The immune response against xenogeneic Igs
has
always been regarded as an undesired side effect of mAb therapy and
strategies
have been devised to avoid it, such as the use of chimeric antibodies
(4)
or the induction of specific tolerance to foreign Ig (5)
.
We
have investigated the possibility that the human T cell response against
mouse
Ig (m1g)' might in some cases be beneficial, rather than detrimental, and
that
it could be exploited to focus an individual's T cells against targets recog-
nized
by the mAb
.
Here
we show that three patients who have been treated with mouse mAb
carry
T cells specific for mfg
.
These T cells are able to recognize and in some
instances
kill target cells that have bound and processed an antitarget mAb
.
Materials
and Methods
Patients.
￿
Patient
A (HLA
:
Al, A31, B8, B37, Cw6, Cw7, DR1, DQwI) bearing a
colon
carcinoma was treated with a single intravenous injection (200 mg) of 17-1A mAb
(IgG2a
specific for an antigen associated with colon carcinoma (6) (Centocor, Malvern,
PA).
He neither suffered adverse reaction, nor developed detectable titers of antibodies
against
mouse Ig
.
Patient B (HLA
:
Al, A2, B7, B8, Cw7, DR1) bearing a colorectal
carcinoma
with lung metastasis was treated with three injections (once 20 mg and twice 2
mg)
of "'I-F023C5 mAb (IgGI anticarcinoembryonicantigen
;
Sorin Biomedica, Saluggia,
Italy).
He developed high titers of antibodies against mouse Ig
.
Patient C (HLA
:
A2, B35,
Bw56,
Cwl, Cw4, DR1, DQwI) had a B cell immunocytoma with a monoclonal IgGlh
paraprotein
(1 mg/ml) in the serum
.
A mouse antiidiotypic mAb ASI20, IgGla was
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prepared (7). PBMC containing 40% idiotype (Id)-positive cells, were obtained before
treatment and stored in liquid nitrogen. Large amounts of tumor cells were isolated by
leukapheresis, incubated overnight with ASI20, washed, and reinfused into the patient.
He neither showed adverse reaction nor developed anti-mIg antibodies. After treatment
3 yr ago the patient went into a slowly proceeding remission of his disease.
Monoclonal Antibodies,
￿
141PF11 (IgGI anti-human K light chain), OKT9 (IgGI anti-
transferrin receptor), W6/32 (IgG2a anti-human MHC class I), DA4.4 (IgGI anti-human
IgM), BBM.1 (IgG2b anti-,B2 microglobulin), 1410KG7 (IgGI anti-human IgG), THB5
(IgG2a anti-CD-21), and 4F2C13 (IgG2a specific for an activation antigen present on
most PBMC) were obtained from the American Type Culture Collection, Rockville, MD.
SKIO (IgGI anti-DQ), B7/21 (IgGI anti-DP), LOL1 (IgG2a anti-transferrin receptor),
NKP15 (IgGI anti-Fcy receptor), and B73.1 (IgGI anti-Fc-y receptor) were obtained
from Becton Dickinson & Co., Mountain View, CA. D4.22 (IgGI anti-human MHC class
II) was a gift of Dr. Roberto Accolla, Ludwig Institute for Cancer Research, Lausanne,
Switzerland. The mAb 3 .35 (IgGI, anti-DC-1) and its IgG2a switch variant G2a.5 were a
kind gift of Dr. Peter Parham (University of Stanford, Stanford, CA). The Ig content in
mAb preparations from ascites or culture supernatants was determined using an ELISA
assay for mouse Ig and class-matched standard Ig preparations. Purified K light chains
were purchased from Bionetics (Charleston, SC).
Cell Cultures.
￿
The medium was RPMI 1640 supplemented with 2 MM L-glutamine, 5
X 10-5 M 2-ME, 1% nonessential amino acids, 1 mM sodium pyruvate, and 50 ug/ml
Kanamycin (complete RPMI). For the growth of human T cell clones the medium was
supplemented with 5% human serum (HS) and 30 U/ml human rIL-2 (Hoffmann-La
Roche, Basel, Switzerland). EBV-transformed B cells were maintained as described (8).
Isolation of T Cell Clones and EBV-B Cells.
￿
PBMC were cultured at 5 X 105/ml in
RPMI-5% HS in the presence or absence ofdifferent mouse mAbs. The mAbs used were:
D4.22, OKT9, and 4F2CI3 at 1 ug/ml in culture. 17-IA or ASI20 were used at I mg/ml.
A vigorous proliferative response was observed and after 7 d the cells were expanded
with IL-2 and cloned by limiting dilution in the presence of irradiated (3,000 rad)
allogeneic PBMC, PHA (Wellcome Diagnostics, Dartford, United Kingdom, I Ag/ml),
and IL-2 (30 U/ml) in 20 Fel cultures in Terasaki trays (8). From the same three donors,
EBV-B cells were isolated and cloned as described (8). The T cell clones obtained were
screened for their capacity to proliferate in response to the mAbs used for stimulation in
the presence of autologous irradiated EBV-B cells as APCs.
Proliferation Assay.
￿
2 X 10' T cells were cultured with 104 irradiated (3,000 rad) EBV-
B cells in 200 I,1 RPMI-10% FCS in 96-well flat-bottomed microplates in the presence or
absence of different mAbs. After 48 h the cultures were pulsed with 0.5 uCi['H]thymidine
(sp act 5 Ci/mmol, Amersham, United Kingdom) and the radioactivity incorporated was
measured after an additional 16 h. In some experiments, EBV-B cells were pulsed with
mAbs for 30 min at O'C, washed, and incubated at 37'C in RPMI-FCS in the presence
or absence of 10 1M chloroquine, or 5 Ag/ml leupeptin (both from Sigma Chemical Co.,
St. Louis, MO). After different times of incubation at 37'C the cells were washed three
times in HBSS and fixed with 0 .05% glutaraldehyde (Fluka, Buchs, Switzerland) for 1
min. The reaction was stopped by adding an equal volume of 0.2 M glycine in HBSS.
When fixed cells were used as APCs the cultures were set up in 96-well U-bottomed plates
essentially as described above.
Cytotoxicity. Cytotoxicity was performed as described (9). Briefly, target cells were
incubated with mAbs for 4 h at 37°C in RPMI-FCS and labeled with "Cr. Targets (5 X
103) and effector cells were mixed at different E/T ratios in 200 A1 RPMI-FCS in 96-well
U-bottomed microplates. The plates were incubated at 37 ° C and samples of supernatants
were collected after 4 h. Spontaneous, maximum (saponin), and experimental release were
measured and specific killing was determined according to the equation: Specific killing
= 100 X [(experimental release - spontaneous release/(maximum release - spontaneous
release)] .LANZAVECCHIA ET AL.
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TABLE I
T Cell Clones SpecificforMouse Ig Determinants
* Mouse Ig-specific T cell clones, originating from three different patients (A,
B, andC),were cultured with autologous irradiated EBV-Bcellsin thepresence
of 10 kg/ml of theanti-DC1 IgGI mAb 3.35, its IgG2aswitch variant G2a.5,
or purified mouse is light chains. ['H]Thymidine incorporation was measured
after 2 d.
Results
Patients Treated with Mouse mAbs Have T Cells Specific for mIg.
￿
PBMC from
three tumor patients that had been treated with antitumor mAbs were stimulated
in vitro with either high concentrations of the originally injected mAb or with
low concentrations of mAbs that bind specifically to APO, i.e., anti-human IgM
or anti-MHC class II. In all three patients we observed a strong proliferative
response to mIg, irrespective of the mAb used for stimulation. In contrast,
normal donors did not show any detectable response. The cells that proliferated
in response to mIg were almost exclusively T cells, as detected by immunoflu-
orescent staining using anti-CD3, CD4, CD8, and WT31 mAb. In general, <10%
of the blast cells were CD8', the rest being CD4+.
The proliferating T cells from the three patients were expanded with IL-2
and cloned. 20-50% of the clones obtained were able to proliferate in response
to mIg in the presence of irradiated autologous PBMC or EBV-B cells as APC.
All the clones were CD3+, WT31+, CD4+, CD8- and lacked Fcy receptors as
detected by the mAbs NKP15 and B73.1 (data not shown). Although we also
sorted and cloned CD8+ cells, we failed to isolate CD8+ clones specific for mIg.
Using as antigens a panel of mAbs of different isotypes, including switch variants
as well as purified K light chains, we found three patterns of specificity (Table 1) .
Some clones recognized mouse IgGI, some IgG2a antibodies, and some purified
K light chains, as well as all of the
K+ mAbs tested. We conclude that in all three
patients the injection of mouse mAb had induced an effective priming of CD4+
T cells against isotypic determinants of the mIg injected. An apparent exception
was patient A, treated with an IgG2a mAb, from which we isolated some IgGl-
specific T cell clones in addition to IgG2a specific ones, We therefore checked
the isotypes present in the antibody preparation used for therapy which was
prepared from ascitic fluid and found that it contained abundant amounts of
mouse IgGI in addition to the original IgG2a mAb.
We asked whether mIg, like conventional antigens, have to be processed by
APCs before they can be recognized by T cells. EBV-B cells were pulsed with
Tcell clone
[sH]Thymidine incorporated in response
3.35 G2a.5
(IgGI) (IgG2a) Mouse K
to:*
Medium
cpm
A158 488 45,250 390 416
A132 72,455 726 480 590
B11 103,051 95,622 91,775 1,025
B13 60,567 1,020 1,459 994
C2 125,750 110,022 135,526 398
C7 95,970 561 415 408348
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TABLE 11
Mouse mAbs Have to be Processed by APCs before they Can Be Recognized by
m1g-specific T Cells
* EBV-B cells from donorC were pulsed at 0°C with anti-IgM (DA4.4)and cells from donor B with
anti-class II (D4.22) both at 10 wg/ml. After 30 min the cells were washed and incubated at 37°C
for the time indicated before being fixedwith glutaraldehyde. Chloroquine (10-5 M) or leupeptin
(5 wg/ml) were added during the incubation at 37°C.
$T cells (2 x 10') from three mIg-specific T cell clones (two from donor C and onefrom donor B)
were incubated with fixed EBV-B cells (5 x 10*) in 200 Al RPMI-FCS in 96-well U-bottomed
microplates. Thymidine incorporation was measured after 2 d.
anti-IgM or anti-MHC class II mAb at 0°C, washed, and incubated at 37°C for
different periods of time before being fixed with glutaraldehyde. As evident
from Table 11, EBV-B cells that had been fixed immediately or after 40 min at
37°C were not stimulatory for T cells, while cells fixed after 120 min at 37°C
were stimulatory. Furthermore, when chloroquine or leupeptin were present
during the incubation at 370C, the APC did not acquire the capacity to trigger
T cells. These experiments indicate that binding ofthe mAb to the APC is not
sufficient and that active metabolic processing events inhibitable by chloroquine
(10) or leupeptin are required for effective presentation ofmIg to T cells. Table
II also shows that recognition ofmIg requires autologous APCs, since allogeneic
APCs were not effective. We therefore tried to inhibit T cell activation using
anti-MHC class II antibodies. In all cases, the proliferative response to mIgcould
be inhibited by a rabbit anti-MHC class II antiserum (11) or by anti-MHC class
II mAbs ofisotypes that were not recognized by the Tcell clone itself (data not
shown). We conclude that mAbs, like conventional protein antigens, are recog-
nized by T cells only in a processed form and in an MHC-restricted fashion.
Selective Presentation ofmAbs that Bind to APCs.
￿
Unlike conventional antigens,
mAbs can bind specifically to selected target structures on APC. We therefore
investigated whether it is possible to use specific mAbs to send the same foreign
antigen (mIg) to a given cell ofchoice so that this cell will subsequently become
a selected target for mIg-specific Tcells.
We therefore determined, for different mAbs, the concentration required for
effective presentation to mIg-specific T cells. Fig. 1 shows the proliferative
response of a T cell clone specific for mouse K chains cultured with irradiated
autologous sIgM+-EBV-B cells in the presence of different concentrations of
mAbs that either bind or do not bind specifically to the B cells. We found that
antibodies that do not specifically bind to APC (anti-IgG, antiidiotype, anti-
APC*
APC
Time at 37°C
after pulsing and
before fixation
min
['H]Thymidine
C2
incorporation
clones$
C7
cpm
by T cell
B11
EBV-B (donor C) 0 80 120 128
40 118 296 88
120 58,273 72,125 95
120 + chloroquine 1,415 2,150 ND
120 + leupeptin 1,112 3,605 ND
EBV-B (donor B) 40 103 ND 166
120 97 ND 42,575100
0
E a
U
m
105
a
7
g lot
2
M
103
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FIGURE 1 .
￿
Selective presentation ofmAbs that bind to APCs. A T cell clone (C2) specific
far mouse x light chains was cultured with irradiated sIgM+ EBV-B cells in the presence of
different concentrations of mAbs that either bind (DA4.4 [0], D4.22 [0], BBM.1 [O], OKT9
[A], THB5 [O]and4F2C13 [V]) or do not bind (17-1A [0), 1410K47 [A], AS120 [*]) to EBV-
B cells . Thymidine incorporation was measured after 2 days .
FIGURE 2 . (a and b) EBV-B
cell clones from patient C
bearing s1gG (a) or s1gM (b)
were pulsed at 37°C for 4 h
with 1 jug/ml anti-IgM (0),
anti-IgG (A), anti-Id (O), or
medium alone (Q), "Cr-la-
beled, and incubated with aT
cell clone (C2) specific for
mouse is light chain . The dot-
ted line represents the lysis of
impulsed cells (bystander) in
the presence of an equal num-
ber of cold targets that had
been pulsed with the appro-
1 .1
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priate mAb(N) . (e) PBMC ob-
E Tratlo
￿
tained before therapy from
patient C, containing -40% Id' cells, were pulsed for 4 h at 37°C with the anti-Id mAb (O) or with
the irrelevant 17-IA mAb (0) both at I Ag/ml or with medium alone (0) . Specific "Cr-release was
measured after4 h . The spontaneous release never exceeded 20%.
colon carcinoma) were presented only at high concentrations (>10 ug/ml) . In
contrast, all the antibodies that bind to the B cells (anti-IgM, anti-MHC class 11,
anti-02 microglobulin, anti-transferrin receptor, anti-CD21, 4F2C13) were pre-
sented to T cells at much lower concentrations ranging from 0.1 to 10 ng/ml .
Targeting T Cells Using mAbs .
￿
The above results suggest that low concentra-
tions of specific mAbs can be used to target mIg-specific T cells against a class
II-positive target of choice . We have further investigated this point by looking
at whether mIg-specific T cells could be induced to selectively kill target cells
that had taken up and processed a specific mousemAb. Since processing ofmIg
has to take place before T cells can recognize them on APC, we first pulsed
target EBV-B cells with low concentrations of mAbs for 4 h at 37 °C. After
labeling with "Cr, EBV-B cells were tested as targets for lysis by autologous T
cell clones specific for mIg. 8 of 20 T cell clones tested showed, in addition to a
specific proliferative capacity, a strong cytotoxic activity in a 4-h "Cr-release
assay. Fig . 2 shows a representative experiment in which an mIg-specific T cell
clone can efficiently lyse B cells that have been incubated with a mAb specific
a SIgG'EBV-B b SI9M'EBV-B C Id'B-Lymphoma
0
O
0
0
n 011001
0
0
"350
￿
ANTIBODIES AS ANTIGENS
for their sIg, whereas it does not lyse B cells that have been incubated with a
mAb that does not bind their sIg. We also investigated whether mIg-specific T
cells are also capable of lysing bystander cells in the process of killing their
specific target. For this we used as targets
51Cr-labeled EBV-B cells that had not
been pulsed with the mAb, and we added, as a "triggering target," cold B cells
that had been pulsed with a specific mAb. Fig. 2 shows thatundertheseconditions
there is only a limited killing of bystander cells.
Theavailability ofan mAb specific for the idiotype ofthe Bcell immunocytoma
ofpatient C gave us the unique opportunity to test whether the results obtained
with EBV-B cells also apply to a fresh B cell tumor. Fig. 2c shows that fresh
tumor cells (ofwhich ^-40% are Id') that have been pulsed with the anti-Id mAb
AS120 can be killed by an mIg-specific T cell clone, while the same tumor cells
pulsed with medium alone or with an irrelevant antibody are not killed. As a
control, the anti-Id at the same concentration does not signal for killing an Id-
EBV-B cell from the same patient (Fig. 2 b).
Discussion
We have found that three tumor patients treated with mouse mAbs have T
cells that recognize processed mIg on autologous APC in a class II-restricted
fashion, and have shown that mouse mAbs directed against various cell surface
molecules can be used as antigens to focus these T cells against an MHC class
11-positive target ofchoice.
The use of antibodies as antigens was pioneered in the mouse system by
Chestnut and Grey (12), who showed that rabbit anti-mouse Ig, which binds
polyclonally to B cells, is presented by B to T cells -10' times more efficiently
than normal rabbit Ig. In a similar system Tony et al. (13) subsequently demon-
strated that anti-MHC class I antibodies can also be presented by B to T cells,
although less efficiently than anti-Ig. In the present study we have used as
antigens mAbs directed against different structures on APC (sIg, class II, class I,
transferrin receptor, 4F2C13 antigen), and found that all ofthem are presented
to T cells at concentrations 103_101 times lower than those required for antibod-
ies that do not bind to APCs. Thus many surface structures on B cells can serve
for antigen internalization and class II-restricted presentation.
The rather large differences in the concentrations required for presentation
among antibodies that bind to APC could be related to several factors such as:
(a) the affinity of the mAbs, (b) the density of the antigen on the APCs, (c) the
nature of the antigen, (d) the degree of crosslinking and (e) the rate of internal-
ization of the complex. Indeed, when the data were normalized by relating the
efficiency of presentation to the amount ofmIg bound to APC at 4°C, we found
that anti-Ig were presented -I0-fold more efficiently than anti-class II or anti-
transferrin receptor antibodies and -100-fold more efficiently than anti-class I
antibodies (Lanzavecchia, A., and S. Abrignani, manuscript in preparation).
Targeting mIg-specific T cells with mAbs can be highly effective and specific
since: (a) different molecules on the cell surface can be used as targets; (b)
targeting is obtained at antibody concentrations as low as 0.1-10 ng/ml; (c) in
the presence of limiting concentrations ofmAbs, T cells interact only with those
class II-positive cells bound by the targeting mAb. Instead, at high antibodyLANZAVECCHIA ET AL.
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concentrations, the selectivity of targeting will be lost, since T cells will be
distracted by antigen presented on every APC.
The limitations ofantigen targeting are obviously connected with the require-
ment for the internalization, processing, and class II-restricted presentation of
mIg. It will be important to determine: (a) whether all cell surface structures
(including tumor-associated antigens) are suitable for T cell targeting by mAbs;
and (b) whether class I1-positive cells that are themselves neither "professional"
APCs nor B cells will be able to process and present mIg to Tcells.
The finding that 40% ofthe mIg-specific T cell clones showed, in addition to
a proliferative activity, a strong MHC class 11-restricted cytotoxicity, deserves
some comments. The rapidcytotoxic effect andthe lack ofbystanderlysis suggest
that these T cell clones use a lytic machinery that is characteristic of typical
cytotoxic Tcells. However, we cannot rule out the possibility that this cytotoxic
activity is acquired as a consequence ofin vitro culture (14). This notwithstand-
ing, it must be emphasized that the T cell recognition ofmIg on target cells also
results in secretion of lymphokines (IL-2 and IFN-y) that have well-known
immunoregulatory effects (data not shown).
The approach of using antibodies as antigens may have one advantage over
that of using antibodies only as passive carriers of destructive elements: that of
boosting the immune response andfocusing it againstthe target ofchoice. There
are examples where the response against a weakly immunogenic determinant
can be elicited only ifanother (helper) determinant is corecognized on the same
cell (15, 16). It is possible that a similar effect of "intermolecular help" may be
elicited by sending the foreign antigen (mIg) to the target cell to boost the
immune response against a weakly immunogenic determinant present on that
same cell.
Summary
We found that three tumor patients treated with mouse mAbs have T cells
that recognize processed mouse Ig on autologous APC in a class 11-restricted
fashion, and we have shown that mouse mAbs directed against various cell
surface molecules can be used as antigens to focus these T cells on an MHC class
I1-positive target ofchoice.
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